Valuation: Abeona Therapeutics Inc.

Market Cap 341M 292M 273M 250M 469M 32.61B 475M 3.23B 1.26B 16.38B 1.28B 1.25B 54.18B P/E 2026 *
-6.3x
P/E 2027 * -31.9x
Enterprise Value 341M 292M 273M 250M 469M 32.61B 475M 3.23B 1.26B 16.38B 1.28B 1.25B 54.18B EV / Sales 2026 *
6.24x
EV / Sales 2027 * 2.86x
Free-Float
79.56%
Yield 2026 *
-
Yield 2027 * -
1 day+2.18%
1 week+1.75%
Current month-5.14%
1 month-6.74%
3 months+10.33%
6 months+17.57%
Current year+15.56%
1 week 5.7
Extreme 5.7
6.32
1 month 5.7
Extreme 5.7
7.65
Current year 4.23
Extreme 4.23
7.65
1 year 4
Extreme 4
7.65
3 years 3.05
Extreme 3.05
9.01
5 years 2.19
Extreme 2.19
34
10 years 2.19
Extreme 2.19
568.75
Manager TitleAgeSince
Chief Executive Officer 50 2021-10-14
Director of Finance/CFO 42 2022-03-13
Chief Tech/Sci/R&D Officer - 2025-10-19
Director TitleAgeSince
Director/Board Member 58 2006-02-28
Director/Board Member 64 2021-03-24
Director/Board Member 63 2021-04-18
Date Insider Type Main position Quantity % Market Cap.
7/21/26 Sell

Chief Financial Officer

-1,478 0.0026%
7/9/26 Sell

Executive/Senior Manager

-12,606 0.0221%
7/9/26 Sell

Chief Financial Officer

-24,880 0.0437%
Change 5-day change 1-year change 3-year change Capi.($)
+2.18%+1.75%-14.35%+60.69% 341M
+0.90%+3.80%+39.43%-1.22% 82.54B
-1.69%+22.38%-23.76%-37.80% 58.38B
+8.86%+129.20%+453.51%+30.65% 53.23B
-1.46%-0.83%-1.01%+30.84% 52.24B
+1.74%+1.19%+13.58%+175.40% 48.52B
+1.13%+3.31%+55.82%-18.22% 31.67B
+0.46%+6.37%+47.71%+96.99% 25.79B
+1.19%+7.62%+8.19%+225.60% 22.46B
-5.74%+0.79%-1.19%+842.24% 16.97B
Average +0.77%+14.57%+57.79%+140.52% 39.21B
Weighted average by Cap. +1.13%+19.95%+75.92%+78.41%

Financials

2026 *2027 *
Net sales 54.61M 46.78M 43.77M 40.06M 75.19M 5.22B 76.18M 517M 202M 2.62B 205M 201M 8.68B 119M 102M 95.55M 87.46M 164M 11.41B 166M 1.13B 440M 5.73B 448M 438M 18.95B
Net income -54.05M -46.3M -43.32M -39.65M -74.42M -5.17B -75.4M -512M -200M -2.6B -203M -199M -8.59B -9.12M -7.81M -7.31M -6.69M -12.56M -873M -12.73M -86.39M -33.69M -438M -34.26M -33.51M -1.45B
Net Debt - -
Logo Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
Employees
226
Date Price Change Volume
26-08-21 US$6.090 +2.18% 889,259
26-08-20 US$5.960 -2.77% 1,227,859
26-08-19 US$6.130 -0.49% 1,300,703
26-08-18 US$6.160 +3.70% 1,325,872
26-08-17 US$5.940 -0.75% 2,095,323
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.960USD
Average target price
18.86USD
Spread / Average Target
+216.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABEO Stock